Brief: Mesoblast Posts Quarter Revenue From Cell Therapy Products $20.6 Million
20/10/2025 02:23
Oct 20 (Reuters) - Mesoblast Ltd MSB.AX: QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT QUARTER REVENUE FROM CELL THERAPY PRODUCTS US$20.6 MILLION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M